消化指南

订阅

MedSci主页 / 所有栏目 / 消化指南

2016 CAP/ASCP指南：胃食管腺癌HER2检测以及临床决策制定

2016-11-01 美国病理学家协会 Arch Pathol Lab Med. 2016 Nov 14.

胃食管

内容介绍： 2016年11月，美国病理学家协会(CAP)、美国临床病理学会(ASCP)以及(ASCO)联合发布了胃食管腺癌HER2检测以及临床决策制定指南。 HER2是目前唯一用于晚期胃食管腺癌患者选择特殊治疗的生物标志物，本文的目的是针对晚期胃食管腺癌患者HER2检测以及临床治疗决策的制定提供循证指导，专家组针对这些内容共提出了11条推荐建议。 拓展指南：[[胃食管|5]]

中文标题：

2016 CAP/ASCP指南：胃食管腺癌HER2检测以及临床决策制定

英文标题：

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.

发布机构：

美国病理学家协会

发布日期：

2016-11-01

简要介绍：

2016年11月，美国病理学家协会(CAP)、美国临床病理学会(ASCP)以及(ASCO)联合发布了胃食管腺癌HER2检测以及临床决策制定指南。

HER2是目前唯一用于晚期胃食管腺癌患者选择特殊治疗的生物标志物，本文的目的是针对晚期胃食管腺癌患者HER2检测以及临床治疗决策的制定提供循证指导，专家组针对这些内容共提出了11条推荐建议。 拓展指南：与胃食管相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2016 CAP/ASCP指南：胃食管腺癌HER2检测以及临床决策制定)] GetToolGuiderByIdResponse(projectId=1, id=3b0f21c001329a5a, title=2016 CAP/ASCP指南：胃食管腺癌HER2检测以及临床决策制定, enTitle=HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology., guiderFrom=Arch Pathol Lab Med. 2016 Nov 14., authorId=null, author=, summary=内容介绍： 2016年11月，美国病理学家协会(CAP)、美国临床病理学会(ASCP)以及(ASCO)联合发布了胃食管腺癌HER2检测以及临床决策制定指南。 HER2是目前唯一用于晚期胃食管腺癌患者选择特殊治疗的生物标志物，本文的目的是针对晚期胃食管腺癌患者HER2检测以及临床治疗决策的制定提供循证指导，专家组针对这些内容共提出了11条推荐建议。 拓展指南：[[胃食管|5]], cover=, journalId=null, articlesId=null, associationId=107, associationName=美国病理学家协会, associationIntro=美国病理学家协会（CAP，College of American Pathologists）是美国一个非赢利的临床实验室认可机构，它依据美国临床检验标准化委员会（CLSI）的业务标准和操作指南，以及1988年的美国临床实验室改进规范（CLIA&rsquo;88），对临床实验室各个学科的所有方面均制定了详细的检查单，通过严格要求来确保实验室符合质量标准，从而改进实验室的实际工作。CAP致力于临床试验室步骤的标准化和改进；倡导高质量和经济有效的医疗保健服务，其所产生的影响超过了其他任何一个组织，因此被国际公认为是实验室质量保证的领导者和权威性的实验室管理和认证组织。, copyright=0, guiderPublishedTime=Tue Nov 01 00:00:00 CST 2016, originalUrl=, linkOutUrl=, content=2016年11月，美国病理学家协会(CAP)、美国临床病理学会(ASCP)以及(ASCO)联合发布了胃食管腺癌HER2检测以及临床决策制定指南。<br><br> HER2是目前唯一用于晚期胃食管腺癌患者选择特殊治疗的生物标志物，本文的目的是针对晚期胃食管腺癌患者HER2检测以及临床治疗决策的制定提供循证指导，专家组针对这些内容共提出了11条推荐建议。 拓展指南：<strong>与<font color="red">胃食管</font>相关指南：</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=5389e1c0013285be" title="2013 AAP临床报告：胃食管反流病儿科医师管理指南" target="_blank">2013 AAP临床报告：胃食管反流病儿科医师管理指南</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=29f851c001285e00" title="2016 亚太共识：胃食管反流病的管理（更新版）-顽固性反流病和Barrett''s食管" target="_blank">2016 亚太共识：胃食管反流病的管理（更新版）-顽固性反流病和Barrett''s食管</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=1310d1c0012e850b" title="2016 CHEST指南：胃食管反流患者引起的慢性咳嗽" target="_blank">2016 CHEST指南：胃食管反流患者引起的慢性咳嗽</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=fec8b1c0012519f8" title="2016 SAR共识声明：胃食管反流病食管钡餐造影检查" target="_blank">2016 SAR共识声明：胃食管反流病食管钡餐造影检查</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=afc371c00123a996" title="2016 NCCN临床实践指南：食道癌和胃食管交界处癌（2016.V2）" target="_blank">2016 NCCN临床实践指南：食道癌和胃食管交界处癌（2016.V2）</a></li> 更多信息请点击：<a href="http://www.medsci.cn/guideline/list.do?q=%E8%83%83%E9%A3%9F%E7%AE%A1" target="_blank">有关胃食管更多指南</a></ul>, tagList=[TagDto(tagId=17681, tagName=胃食管)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=24, categoryName=胸心外科, tenant=100), CategoryDto(categoryId=76, categoryName=胃肠外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=1, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2980, appHits=180, showAppHits=18, pcHits=2176, showPcHits=1292, likes=133, shares=12, comments=5, approvalStatus=1, publishedTime=Wed Nov 16 16:38:36 CST 2016, publishedTimeString=2016-11-01, pcVisible=1, appVisible=1, editorId=5295955, editor=yingzheng.gu, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=yingzheng.gu, createdTime=Wed Nov 16 16:38:36 CST 2016, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 16:15:59 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2016 CAP/ASCP指南：胃食管腺癌HER2检测以及临床决策制定)])
2016 CAP/ASCP指南：胃食管腺癌HER2检测以及临床决策制定
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=157917, encodeId=368a15e91786, content=学习了好东西！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Thu Nov 24 18:56:13 CST 2016, time=2016-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157592, encodeId=79dc15e59205, content=感谢梅斯医学, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Wed Nov 23 09:23:33 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157521, encodeId=803f15e52158, content=I make a great progress I have gained a lot, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Tue Nov 22 21:34:45 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157520, encodeId=53e215e52088, content=I make a great progress I have gained a lot, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Tue Nov 22 21:34:08 CST 2016, time=2016-11-22, status=1, ipAttribution=)]
    2016-11-24 thlabcde

    学习了好东西！

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=157917, encodeId=368a15e91786, content=学习了好东西！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Thu Nov 24 18:56:13 CST 2016, time=2016-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157592, encodeId=79dc15e59205, content=感谢梅斯医学, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Wed Nov 23 09:23:33 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157521, encodeId=803f15e52158, content=I make a great progress I have gained a lot, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Tue Nov 22 21:34:45 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157520, encodeId=53e215e52088, content=I make a great progress I have gained a lot, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Tue Nov 22 21:34:08 CST 2016, time=2016-11-22, status=1, ipAttribution=)]
    2016-11-23 cqykthl

    感谢梅斯医学

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=157917, encodeId=368a15e91786, content=学习了好东西！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Thu Nov 24 18:56:13 CST 2016, time=2016-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157592, encodeId=79dc15e59205, content=感谢梅斯医学, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Wed Nov 23 09:23:33 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157521, encodeId=803f15e52158, content=I make a great progress I have gained a lot, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Tue Nov 22 21:34:45 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157520, encodeId=53e215e52088, content=I make a great progress I have gained a lot, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Tue Nov 22 21:34:08 CST 2016, time=2016-11-22, status=1, ipAttribution=)]
    2016-11-22 zibozhouping

    I make a great progress I have gained a lot

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=157917, encodeId=368a15e91786, content=学习了好东西！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Thu Nov 24 18:56:13 CST 2016, time=2016-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157592, encodeId=79dc15e59205, content=感谢梅斯医学, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Wed Nov 23 09:23:33 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157521, encodeId=803f15e52158, content=I make a great progress I have gained a lot, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Tue Nov 22 21:34:45 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157520, encodeId=53e215e52088, content=I make a great progress I have gained a lot, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Tue Nov 22 21:34:08 CST 2016, time=2016-11-22, status=1, ipAttribution=)]
    2016-11-22 zibozhouping

    I make a great progress I have gained a lot

    0

相关指南

2015 NICE指南：儿童和青年胃食管反流病的识别，诊断和管理（NG1）

暂未更新 · 2015-01-14